论文部分内容阅读
本文中,Kitby RS对多沙唑嗪在伴有高血压的良性前列腺增生(BPH)患者中的应用作了综述。许多研究已证明选择性α1-肾上腺素受体阻滞剂治疗BPH的疗效显著。和其它的选择性α1-肾上腺素受体阻滞剂相比,多沙唑嗪血浆半衰期较长。多沙唑嗪除了能明显增加平均和最大尿流量外,能明显降低最大排泄压、明显改善尿频、尿急、夜尿症,尿流下降和尿不尽感。无论血压正常还是合并高血压的BPH患者,使用多沙唑嗪后,除了能明显降低高血压患者血压外,在尿流量和症状改善方面疗效相似。血压正常的和高血压BPH患者对多沙唑嗪均有较好的耐受性。由于多沙唑嗪独特的量效曲线,对于许多由于BPH引起的膀胱流川道梗阻的患者,多沙唑
In this article, Kitby RS reviewed the use of doxazosin in patients with benign prostatic hyperplasia (BPH) associated with hypertension. Many studies have shown that selective α1-adrenergic receptor blocker treatment of BPH significant effect. Doxazosin has a longer plasma half-life compared with other selective α1-adrenergic blockers. Doxazosin can not only significantly increase the average and maximum flow of urine, can significantly reduce the maximum excretion pressure, significantly improved urinary frequency, urgency, nocturia, decreased urinary flow and urinary tract infection. In patients with BPH, whether normotensive or with hypertension, use of doxazosin not only markedly reduced blood pressure in hypertensive patients, but also showed similar effects in terms of urinary flow and symptom improvement. Patients with normotensive and hypertensive BPH are more tolerant of doxazosin. Due to the unique dose-response curve of doxazosin, for many patients with BPH-induced bladder flow obstruction, doxazosin